MétaCan
Menu
Cohort builder

4,299,418 works, Canadian by any of four routes.

Every filter state is a URL; the URL is the query; the query is citable via /q/⟨hash⟩. The page, the API and the export parse the same parameters.

The current cohort, streamed from the database: every work column, the machine labels, the provisional scores, and the per-row validation status. Exports are capped at 100,000 rows. Mints a permanent /q/ link for this exact query. The same filters always produce the same link, whoever asks.

Search term
Author
Year range
Sort
Language
Type
Field
Venue
Clinical Lymphoma Myeloma & Leukemia
Topic
Retraction
Abstract
Evidence source
Study design
Label agreement
Label status

Direct Codex and Gemma labels are unvalidated and sparse. Distilled predictions cover the full frame and are also unvalidated. Choose the evidence source explicitly; absence of a direct label is never a negative label.

affaffiliation
fundfunder
venuejournal
aboutaboutness

The four routes compose: require the funder route and exclude affiliation to get the funder-only stratum no affiliation-based frame ever sees.

503 results · 1 filter active ·
Results by year
20102025
Publication date
Categories
Machine labels · sparse coverage
Evidence
Language
Type
Citations
An unlabeled work is unknown, not a negative. Label coverage is reported on every query.
503 works in the cohort · of 4,299,418page 8 of 11

Labels cover 1 of 503 works in this cohort. The rest are unlabeled, which is not a negative label: the label table is sparse today and grows as labeling rounds land.

Distilled predictions cover 503 of 503 works in this cohort. Predictions are machine_predicted_unvalidated. The Gemma side is a direct model label for every work (title-only); the Codex side is a distilled, calibrated classifier. Candidate is the union; consensus is the intersection.

affno abstractunlabeled
Oral Abstract: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Christopher R. Flowers, Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný +26 more
2022· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Poster: AML-432 Overall Survival (OS) by IDH2 Mutant Allele (R140 or R172) in Patients With Late-Stage, Mutant-IDH2 Relapsed/Refractory Acute Myeloid Leukemia (AML) Treated With Enasidenib or Conventional Care Regimens (CCR) in the Randomized, Open-Label, Phase 3 IDHENTIFY Trial
Courtney D. DiNardo, Stéphane de Botton, Alberto Risueño, Andre C. Schuh, Bob Löwenberg, Hee‐Je Kim +11 more
2022· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
POSTER: CML-315 Assessment of Number Needed to Treat (NNT) and Cost per Response (CpR) in Patients (pts) With Relapsed/Refractory (R/R) Chronic Phase Chronic Myeloid Leukemia (CP-CML) Managed With Ponatinib (PON), Asciminib (ASC), and Bosutinib (BOS)
Elias Jabbour, Fei Huang, Michael J. Zoratti, Megan J. Rutherford, Hoora Moradian, Mehul Dalal +2 more
2023· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
MM-128: Carfilzomib, Dexamethasone, and Daratumumab (KdD) Versus Carfilzomib and Dexamethasone (Kd) in Relapsed or Refractory Multiple Myeloma (RRMM): Subgroup Analysis of the Phase 3 CANDOR Study by Number of Prior Lines of Therapy (pLOTs) and Prior Therapies
Hang Quach, Ajay K. Nooka, Olga Samoylova, Christopher P. Venner, Kihyun Kım, Thierry Façon +9 more
2020· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
afffundno abstractunlabeled
IBCL-458 Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study
Nancy L. Bartlett, Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri +14 more
2023· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study
Laurie H. Sehn, Matthew J. Matasar, Stephen J. Schuster, Sarit Assouline, Pratyush Giri, John Kuruvilla +14 more
2022· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
Poster: ABCL-073 Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (R-CHOP) Therapy in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results From the Phase III POLARIX Study
Christopher R. Flowers, Hervé Tilly, Franck Morschhauser, Laurie H. Sehn, Jonathan W. Friedberg, Marek Trněný +26 more
2022· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
POSTER: AML-521 The Randomized Phase III SIERRA (Study of Iomab-B in Elderly Relapsed or Refractory AML) Trial: Successful Allogeneic Hematopoietic Stem Cell Transplantation Using Treatment With Iomab-B-Led Regimen for Patients With Active, Relapsed or Refractory AML With Failed Targeted Therapies
Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille N. Abboud, Nebu Koshy +34 more
2023· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
MM-1485: DREAMM-8 Study of Belantamab Mafodotin Plus Pomalidomide and Dexamethasone vs Pomalidomide Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma: A Subgroup Analysis in Patients With High-Risk Cytogenetic Abnormalities
Suzanne Trudel, Meral Beksaç, Luděk Pour, Sosana Delimpasi, Hang Quach, Vladimir Vorobyev +11 more
2025· article· en· Clinical Lymphoma Myeloma & Leukemia· Medicine
machine prediction:candidate · noneconsensus · none
0
citations
affno abstractunlabeled
AML-123: Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Engraftment in Older Patients with Active, Relapsed, or Refractory (rel/ref) AML: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 SIERRA Trial
Boglarka Gyurkocza, Rajneesh Nath, Patrick J. Stiff, Edward Agura, Mark R. Litzow, Ben K. Tomlinson +18 more
2020· article· en· Clinical Lymphoma Myeloma & Leukemia· Biochemistry, Genetics and Molecular Biology
machine prediction:candidate · noneconsensus · none
0
citations

How this was built: Screen · Findings · About